scholarly journals Epistemic Corruption, the Pharmaceutical Industry, and the Body of Medical Science

2021 ◽  
Vol 6 ◽  
Author(s):  
Sergio Sismondo
Keyword(s):  
Pharmaceutical Industry ◽  
Conflicts Of Interest ◽  
Medical Science ◽  
Knowledge System ◽  
The Body ◽  
Medical Community ◽  
Pharmaceutical Companies ◽  
Abundant Evidence

When a knowledge system importantly loses integrity, ceasing to provide the kinds of trusted knowledge expected of it, we can label this epistemic corruption. Epistemic corruption often occurs because the system has been co-opted for interests at odds with some of the central goals thought to lie behind it. There is now abundant evidence that the involvement of pharmaceutical companies corrupts medical science. Within the medical community, this is generally assumed to be the result of conflicts of interest. However, some important ways that the industry corrupts are not captured well by standard analyses in terms of conflicts of interest. It is not just that there is a body of medical science perverted by industry largesse. Instead, much of the corruption of medical science via the pharmaceutical industry happens through grafting activities: Pharmaceutical companies do their own research and smoothly integrate it with medical science, taking advantage of the legitimacy of the latter.

The Ethics of Accepting Gifts from Pharmaceutical Companies

PEDIATRICS ◽  
1991 ◽  
Vol 88 (6) ◽  
pp. 1233-1237
Author(s):  
Lewis H. Margolis
Keyword(s):  
Pharmaceutical Industry ◽  
Medical Community ◽  
Pharmaceutical Companies ◽  
Ongoing Debate ◽  
The Subject

How physicians respond to the promotional activities of the pharmaceutical industry is the subject of ongoing debate and controversy. This paper postulates that the acceptance of gifts in virtually any form violates fundamental duties of the physician of nonmaleficence, fidelity, justice, and self-improvement. The medical community must articulate this position clearly, and it should act accordingly.

scholarly journals A hidden web of policy influence: The pharmaceutical industry’s engagement with UK’s All-Party Parliamentary Groups

PLoS ONE ◽  
2021 ◽  
Vol 16 (6) ◽  
pp. e0252551
Author(s):  
Emily Rickard ◽  
Piotr Ozieranski
Keyword(s):  
Pharmaceutical Industry ◽  
Conflicts Of Interest ◽  
Pharmaceutical Companies ◽  
Total Drug ◽  
Conflicts Of Interests ◽  
Policy Influence ◽  
Patient Organisations ◽  
Drug Companies ◽  
Health Related ◽  
Industry Needs

Our objective was to examine conflicts of interest between the UK’s health-focused All-Party Parliamentary Groups (APPGs) and the pharmaceutical industry between 2012 and 2018. APPGs are informal cross-party groups revolving around a particular topic run by and for Members of the UK’s Houses of Commons and Lords. They facilitate engagement between parliamentarians and external organisations, disseminate knowledge, and generate debate through meetings, publications, and events. We identified APPGs focusing on physical or mental health, wellbeing, health care, or treatment and extracted details of their payments from external donors disclosed on the Register for All-Party Parliamentary Groups. We identified all donors which were pharmaceutical companies and pharmaceutical industry-funded patient organisations. We established that sixteen of 146 (11%) health-related APPGs had conflicts of interest indicated by reporting payments from thirty-five pharmaceutical companies worth £1,211,345.81 (16.6% of the £7,283,414.90 received by all health-related APPGs). Two APPGs (Health and Cancer) received more than half of the total value provided by drug companies. Fifty APPGs also had received payments from patient organisations with conflicts of interest, indicated by reporting 304 payments worth £986,054.94 from 57 (of 84) patient organisations which had received £27,883,556.3 from pharmaceutical companies across the same period. In total, drug companies and drug industry-funded patient organisations provided a combined total of £2,197,400.75 (30.2% of all funding received by health-related APPGs) and 468 (of 1,177–39.7%) payments to 58 (of 146–39.7%) health-related APPGs, with the APPG for Cancer receiving the most funding. In conclusion, we found evidence of conflicts of interests through APPGs receiving substantial income from pharmaceutical companies. Policy influence exerted by the pharmaceutical industry needs to be examined holistically, with an emphasis on relationships between actors potentially playing part in its lobbying campaigns. We also suggest ways of improving transparency of payment reporting by APPGs and pharmaceutical companies.

scholarly journals Pharmacogenomics- The Promise of Personalized Medicine

2013 ◽  
Vol 12 (4) ◽  
pp. 346-356 ◽  
Author(s):  
M Fakruddin ◽  
A Chowdhury
Keyword(s):  
Side Effects ◽  
Personalized Medicine ◽  
Development Process ◽  
Genetic Basis ◽  
Ethical Issues ◽  
Medical Science ◽  
Medical Community ◽  
Pharmaceutical Companies ◽  
Current Therapies ◽  
Genetic Makeup

Introduction: Pharmacogenomics (PGx) is the study of the genetic basis of variability among individuals in response to drugs. It is the newest discipline of medicine and is becoming a very active area of research, with the pharmaceutical industry gaining experience applying it, integrating it into the drug development process, and also learning to better manage the expectations of the medical community. Methodology: A comprehensive review of the literature on the principles, applications, challenges and prospects of pharmacogenomics was performed. Results: Pharmacogenomics tailors therapies to the genetic makeup of an individual and can therefore offer treatments that are more efficacious and have fewer side effects. Despite these benefits, personalized medicine has not been embraced by large pharmaceutical companies. It is expected that the first wave of successful pharmacogenomics products will be used in acute treatments for which current therapies have and severe side effects. These products should also be good candidates for premium pricing. Personalized medicine (PM), based on the genetic makeup of a patient, may result in not only an improved therapeutic response but also a clinically important reduction in adverse drug reactions. The experience to date is mixed, with a few successes but many frustrations. Conclusion: However, for pharmacogenomics to be truly embraced, the benefits of this technology must become more widely accepted in terms of economic, public, regulatory and ethical issues. DOI: http://dx.doi.org/10.3329/bjms.v12i4.11041 Bangladesh Journal of Medical Science Vol. 12 No. 04 October ’13 Page 346-356

scholarly journals Involvement of Probiotics and Postbiotics in the Immune System Modulation

Biologics ◽  
2021 ◽  
Vol 1 (2) ◽  
pp. 89-110
Author(s):  
Neslihan Yeşilyurt ◽  
Birsen Yılmaz ◽  
Duygu Ağagündüz ◽  
Raffaele Capasso
Keyword(s):  
Immune System ◽  
Pharmaceutical Industry ◽  
Intestinal Microbiota ◽  
Health Benefits ◽  
The Body ◽  
Future Research ◽  
Immune Systems ◽  
Advantages And Disadvantages ◽  
Immune System Modulation ◽  
Molecular Patterns

Intestinal microbiota interacts with other systems, especially the immune system, which is responsible for protecting the body by recognizing “stranger” (pathogen associated molecular patterns-PAMPs) and “danger” (damage-associated molecular patterns-DAMPs) molecular motifs. In this manner, it plays an important role in the pathogenesis of various diseases and health. Despite the use of probiotics that modulate the intestinal microbiota in providing health benefits and in the treatment of diseases, there are some possible concerns about the possibility of developing adverse effects, especially in people with suppressed immune systems. Since probiotics provide health benefits with bioactive compounds, studies are carried out on the use of products containing non-living probiotic microorganisms (paraprobiotics) and/or their metabolites (postbiotics) instead of probiotic products. It is even reported that these microbial compounds have more immunomodulatory activities than living microorganisms via some possible mechanism and eliminates some disadvantages of probiotics. Considering the increasing use of functional foods in health and disease, further studies are needed with respect to the benefits and advantages of parabiotic and/or postbiotic use in the food and pharmaceutical industry as well as immune system modulation. Although probiotics have been extensive studied for a long time, it seems that postbiotics are promising tools for future research and applications according to the recent literature. This review aimed to evaluate the interaction of probiotics and postbiotics with the immune systems and also their advantages and disadvantages in the area of food-pharmaceutical industry and immune system modulation.

scholarly journals Cardiovascular risks awareness in coaches and amateur athletes

2021 ◽  
Vol 28 (Supplement_1) ◽  
Author(s):  
A Markovich ◽  
O Mironova
Keyword(s):  
Physical Activity ◽  
Cardiovascular Diseases ◽  
Heart Attack ◽  
Conflicts Of Interest ◽  
The Body ◽  
Treadmill Test ◽  
Cardiovascular Risks ◽  
Sports Cardiology ◽  
Long Distance ◽  
Endurance Sport

Abstract Funding Acknowledgements Type of funding sources: None. Background Regular physical activity is an important component of therapy for most сardiovascular diseases and is associated with reduced cardiovascular and all-cause mortality. The promotion of the physical activity and regular exercise is an important preventive measure that affects the prognosis. Purpose To assess the awareness of the prevalence of cardiovascular disease in exercising population and its influence on the safety of the patients and healthy adults among coaches and people actively engaged in sports activities. Methods An open non-randomized observation was conducted. The questionnaire created by our team included 45 questions about cardiovascular diseases and sport. 111 athletes and coaches aged from 19 to 46 were enrolled in the study. 61,5% (68) are men and 38,5% (42) of the respondents are women. 30,3% (33) of the respondents are coaches. 45,5% (15) of them have over 5 years of coaching experience. 44% (48) of all respondents prefer endurance sport, 25,7% (28) train strength exercise. 63,6% (70) train 3-8 hours per week, 12,7% (14 [7 women and 7 men]) train more than 8 hours each week. Results 18,5% (20 [6 women and 14 men]) think that ECG is enough for screening for cardiovascular diseases. 20% (4) of them are coaches. Only 69,5% (77) of all respondents know about treadmill test. And 41,6% (32/77) of them know about the necessary screening for arrhythmogenic condition. 13% (10/77) of them train more than 8 hours per week. And only 27,3% (21/77) of people who know about treadmill test, passed it themselves. Also 21,6% (24) of all respondents think that any episode of arrhythmia is the  contraindication for any sport. But 96,4% (107) of the respondents know that it is necessary to regularly screen the cardiovascular system, even in the absence of complaints. 9% (10) of the interviewed think that diet is not important for people with cardiovascular diseases. And 18,9% (21) of the respondents don’t know about the effect of electrolytes on the body and the work of the heart muscle. Only 53,2% (59 [21 women and 38 men]) of the respondents trust the doctors more than coaches or themselves. And this is one of the reasons why it is necessary to talk about the basic principles of sports cardiology not only to doctors. 8,1% (9) of the respondents have never heard about any cases of sudden death of an athlete during training or at competitions due to «heart problems». 63,6% (21) of the coaches would not train a person who has suffered a heart attack. 71,8% (56) of the sportsmen would like to return to training after a heart attack. Conclusions Despite the fact that most people prefer a sedentary lifestyle, high-intensity fitness and long-distance endurance sport is getting more popular. Our survey proves the relatively low level of education about the underlying health conditions and possible risks associated with sports not only among  athletes but  professional coaches as well. There are no conflicts of interest to declare.

scholarly journals Strategic account management as a value co-creation selling model in the pharmaceutical industry

2017 ◽  
Vol 32 (2) ◽  
pp. 310-325 ◽  
Author(s):  
Francois Pilon ◽  
Elias Hadjielias
Keyword(s):  
Pharmaceutical Industry ◽  
Pharmaceutical Company ◽  
Value Added ◽  
Pharmaceutical Companies ◽  
Design Data ◽  
Content Type ◽  
Qualitative Research Design ◽  
Account Management ◽  
A Value ◽  
Key Accounts

Purpose This study aims to explore the dynamics enabling strategic account management (SAM) to function as a value co-creation selling model in the pharmaceutical industry. Design/methodology/approach Using an inductive qualitative research design, data are collected within 11 industry customers in Canada. This work focuses on hospitals as strategic accounts of pharmaceutical companies, exploring SAM value co-creation in the “hospital-pharmaceutical company” relationship. Findings The findings suggest the presence of two key dimensions that can enable a value co-creation SAM model in the hospital-pharmaceutical relationship: “customer-tailored value-added initiatives” and “relationship enhancers”. Customer-tailored value-added initiatives explain the activities that are central to the hospital-pharmaceutical company relationship and can lead to the provision of value added that is unique to the hospital. Relationship enhancers explain the activities that can help strengthen hospital-pharmaceutical company relations in the pursuit of enhanced value-added interactions between the two parties. The research demonstrates a cyclical relationship between “customer-tailored value-added initiatives” and “relationship enhancers”, leading to value co-creation through a SAM model. Practical implications The study informs pharmaceutical industry practitioners on how to improve their value proposition through new, more sustainable selling practices. It offers information on implementing a value co-creation SAM model, which can enable pharmaceutical companies to sustain long-lasting value-added relationships with key accounts such as hospitals. Originality/value The study contributes to the field of SAM by conceptualizing SAM as a value co-creation system. It introduces new knowledge in pharmaceutical marketing by offering empirical insight on the applicability and use of SAM in the hospital-pharmaceutical company dyad.

Happy families in the pharmaceutical industry

1983 ◽  
Vol 21 (20) ◽  
pp. 77-79
Keyword(s):  
Pharmaceutical Industry ◽  
Pharmaceutical Products ◽  
Pharmaceutical Companies ◽  
Parent Companies

Many large pharmaceutical companies operate subsidiaries or divisions with separate names and identities. Some of these subsidiaries have been specially created while others are survivors, in name, of take-overs or mergers. This has led to an increase in the number of trading companies promoting pharmaceutical products and to the practice of transferring established products from the parent companies to their subsidiaries. The results of the proliferation and re-organisation of companies will affect prescribers.

Targeting Lyme

2014 ◽  
Vol 19 (4) ◽  
pp. 360-365 ◽  
Author(s):  
David Birnbaum
Keyword(s):  
Lyme Disease ◽  
Development Process ◽  
Conflicts Of Interest ◽  
Guideline Development ◽  
Medical Community ◽  
Diagnostic Tools ◽  
Content Type ◽  
Guideline Development Process ◽  
Vested Interests ◽  
The Usa

Purpose – The purpose of this paper is to describe recent passage of a private member's bill that can put Canada on a different path from the USA in attempting to resolve conflict that arose over how an influential clinical practice guideline for Lyme disease was developed. Design/methodology/approach – Narrative review. Findings – Critical appraisal of pertinent scientific literature is fundamental to the production of evidence-based practice guidelines. Perception of fairness and transparency in a guideline development process is fundamental to wide acceptance. Allegations of conflicts of interest and excluding opposing views in development of Lyme disease guidelines led to legislative interventions after insurers started basing denial of claims and licensing boards started responding to complaints against physicians whose treatment regimens were inconsistent with guideline statements on chronic Lyme disease. Opposing sides are both faced with limitations in available research evidence. Claims and counterclaims about availability of impartial subject matter experts free of vested interests arose; however, this has been compounded by failures in communication channels. Perhaps most importantly, and the focus of this viewpoint, wide perception among those afflicted of a flawed guideline development process makes it unlikely that all sides can reach agreement on this path. Canada, unlike the USA, is taking steps to include all stakeholders (including representatives of the medical community and of patients’ groups) in a review meeting to develop a comprehensive national framework. Research limitations/implications – This situation provides a noteworthy example of defining best practice in the difficult situations where stakes are high, diagnostic tools are flawed, some of those identified as experts have vested interests, and patients with unmet needs feel excluded. Originality/value – The next steps in Canada bear watching, both in terms of potentially resolving key conflicts around the one guideline document in question, and also as a potential model for a more successful guideline development process.

Do innovative activities matter to Indian drug and pharmaceutical firms? An application to export performance

2017 ◽  
Vol 13 (4) ◽  
pp. 193-205
Author(s):  
Shilpi Tyagi ◽  
DK Nauriyal
Keyword(s):  
Pharmaceutical Industry ◽  
Rapid Growth ◽  
Export Performance ◽  
Innovative Activity ◽  
Financial Data ◽  
Pharmaceutical Companies ◽  
Firm Level ◽  
The Real ◽  
Pharmaceutical Firms ◽  
New Evidence

This paper analyzes the R&D and exports profile of Indian drug and pharmaceutical industry during the period 2000–2014. The present paper examines how R&D expenditure and patent impact export performance of the Indian drug and pharmaceutical firms. The study period from 2000 to 2014 has been characterized by a rapid growth in industry’s innovative activity, as part of the strategic shift, induced by the Patents (Amendment) Act, 2005. Using the real financial data for the top 91 publicly listed Indian domestic pharmaceutical companies, the study provides new evidence on firm-level export performance of the Indian drugs and pharmaceutical industry. Generalized Method of Movements estimator developed by Blundell and Bond is applied. The empirical findings of the study reveal that increased R&D intensity, higher patent count and firm’s size are important determinants of firm-level export performance.

scholarly journals CONCEPTS OF MAMSA MARMA - A REVIEW ARTICLE

2021 ◽  
Vol 9 (9) ◽  
pp. 2209-2212
Author(s):  
Mahesh Kumar ◽  
Priyanka 2 ◽  
S. S. Gupta
Keyword(s):  
Medical Science ◽  
Review Article ◽  
The Body ◽  
Anatomical Location ◽  
Practical Application ◽  
Way Of Life ◽  
Vital Part ◽  
The World

Ayurveda is one of the most ancient medical science in the world. Ayurveda is known as the science of life. It is not only medical science, but it is also a way of life. In Ayurvedic literature many Aacharyas (Sage) like Atreya Punarvashu,Dhanvantari,Sushruta,Charaka,Vagbhata and other commentators of samhitas (Ancient iterature) have made, its importance the knowledge of Sharir (body) to have undoubtedly for the sake of knowledge. In Ayurveda, Rachana sharir is a very important part of this science to make a person a good physician or a good surgeon. In Rachana Sharir, Marma sharir is very important topic. By knowing this, a person may become a good physician or surgeon. Marma sharir and its practical application are very important during surgery and to understand the injury at marma site, their prognosis and possible prevention is necessary. Inside the body, there is a specific anatomical location which is called a vital point. Keywords: Mamsa (muscle), marma (vital part), jivsthan (life site), Parinam (result), pariman (dimension)

Sign in / Sign up

Export Citation Format

Share Document